GDF-11

GDF-11 is a secreted ligand of the TGF-β superfamily. It binds to activin type II receptors (ActRIIA/ActRIIB) and triggers, via type I receptors, an intracellular SMAD2/3 signaling cascade. The mature GDF-11 domain is approximately 90% homologous to myostatin (GDF-8); both activate largely the same signaling pathway, which considerably complicates the biological interpretation and, in particular, the measurement. This close kinship is the central reason why early "GDF-11-specific" findings were later called into question – the antibodies/aptamers used in part also reacted with myostatin (cross-reactivity).

The central methodological problem is assay specificity: because of the high homology between GDF-11 and myostatin (GDF-8), early antibody- and aptamer-based measurements could not reliably separate the two factors. Later specific methods (e.g., LC-MS/MS) in part yielded opposite results regarding age dependence. Findings on GDF-11 are therefore interpretable only with consideration of the respective measurement method used.

In 2013, Loffredo et al. (Cell) described GDF-11 as a circulating factor that reverses age-related cardiac hypertrophy in mice. In 2014, Sinha et al. (Science) on skeletal muscle and Katsimpardi et al. (Science) on the vascular and neurogenic "rejuvenation" of the brain followed – works originating, among others, from the circle of Amy Wagers, Richard Lee, and Lee Rubin (Harvard). This "young blood" narrative generated a major media response. From 2015 onward, counter-findings emerged: Egerman et al. (Cell Metabolism, 2015) reported that GDF-11 increases with age and inhibits muscle regeneration, and pointed to cross-reactivity of the detection reagents previously used. Smith et al. (Circulation Research, 2015) found no cardioprotective effect. Schafer et al. (Cell Metabolism, 2016) showed, using a specific mass-spectrometric assay, that GDF-11 does not decline with age in humans. The body of evidence has since been considered contradictory.

• Cardiovascular (age-related cardiac hypertrophy): originally described as protective (Loffredo 2013), but not confirmed in independent works (Smith 2015). Purely preclinical and contradictory.
• Skeletal muscle/regeneration: initially presented as rejuvenating (Sinha 2014), reported to the contrary as inhibiting muscle regeneration and increasing with age (Egerman 2015). Contradictory.
• Brain/neurogenesis and vasculature: described in mice as promoting vascular remodeling and neurogenesis (Katsimpardi 2014); independent confirmation in humans is lacking. Preclinical and unconfirmed.
• Aging/biomarker: whether GDF-11 levels decline with age in humans is unresolved – specific measurements found no decline, but in part associations with frailty and higher risk (Schafer 2016).

• The body of evidence is contradictory: some animal studies reported favorable effects (heart, muscle, brain), while others found no or opposite effects.
• In preclinical works, GDF-11 was associated with an inhibition of muscle regeneration and a reduction of satellite cell expansion (Egerman 2015).
• Observations in humans linked higher GDF-11/myostatin levels with comorbidity, frailty, and elevated operative risk in older cardiovascular patients (Schafer 2016) – an association, not proof of effect.
• Robust clinical safety data in humans from controlled studies are not available.